| Literature DB >> 33728760 |
Yukiko Onishi1, Yoko Yoshida1, Toshiko Takao1, Tazu Tahara1, Takako Kikuchi1, Toshiko Kobori1, Tetsuya Kubota1, Asuka Shimmei1, Masahiko Iwamoto1, Masato Kasuga1.
Abstract
The purpose of this retrospective cohort study at a Tokyo diabetes clinic was to evaluate the effect of telemedicine and clinic visit on glycated hemoglobin (HbA1c) during the coronavirus disease 2019 state of emergency. The effect of telemedicine and clinic visit during the emergency period on the post-emergency measured HbA1c was evaluated by multiple regression models and logistic regression models adjusted for age, sex, type of diabetes, pre-emergency HbA1c and body mass index, and body mass index change during the emergency period. Among 2,727 patients who visited the clinic before and after the emergency period, the interval between clinic visits during the emergency period was significantly associated with HbA1c improvement. Telemedicine and clinic visit were independently associated with HbA1c improvement when pre-emergency HbA1c was ≥7%. In conclusion, clinic visit and telemedicine during the coronavirus disease 2019 emergency period were both independently effective in HbA1c improvement in Japanese diabetes patients who had insufficient HbA1c control.Entities:
Keywords: COVID-19 pandemic; Glycated hemoglobin; Telemedicine
Mesh:
Substances:
Year: 2021 PMID: 33728760 PMCID: PMC8250655 DOI: 10.1111/jdi.13546
Source DB: PubMed Journal: J Diabetes Investig ISSN: 2040-1116 Impact factor: 3.681
Figure 1Clinic follow‐up status of diabetes patients 8 weeks before the coronavirus disease 2019 pandemic emergency period (pre‐emergency period, from 11 February to 6 April 2020), during the state of emergency period (from 7 April to 25 May 2020) and 8 weeks after the emergency period (post‐emergency period, from 26 May to 20 July 2020). There were 3,150 patients who visited our clinic during the pre‐emergency period. Among those 3,150, 605 did not visit during the emergency period, 878 visited the clinic during the emergency period, 1,063 utilized telemedicine between the pre‐ and post‐emergency period visits, and 181 had both clinic visit and telemedicine, and all of these patients visited the clinic again during the post‐emergency period. There were 174 patients who had no contact during the emergency period or post‐emergency period, and 249 patients who had clinic visit and/or telemedicine during the emergency period, but did not visit during the post‐emergency period. A total of 2,727 patients comprised the analytic cohort.
Characteristics of study participants according to HbA1c level at pre‐period (pre‐HbA1c)
| Characteristics | Total ( | Pre‐HbA1c ≥7.0% ( | Pre‐HbA1c <7.0% ( |
|---|---|---|---|
| Age (years) | 68.6 (59.0, 75.5) | 68.7 (58.9, 75.8) | 68.3 (59.5, 75.2) |
| Male sex | 2157 (79.1) | 1348 (77.4) | 809 (82.0) |
| Type 2 diabetes | 2556 (93.7) | 1594 (91.6) | 962 (97.6) |
| No clinic visit nor telemedicine | 605 (22.2) | 335 (19.2) | 270 (27.4) |
| Only clinic visit during emergency period | 878 (32.2) | 610 (35.0) | 268 (27.2) |
| Only telemedicine between pre‐ and post‐visits | 1063 (40.0) | 668 (38.4) | 395 (40.1) |
| Both clinic visit and telemedicine | 181 (6.6) | 128 (7.4) | 53 (5.3) |
| Pre‐BMI (kg/m2) | 24.2 (22.0, 26.6) | 24.3 (22.1, 26.8) | 23.9 (21.8, 26.4) |
| Pre‐HbA1c (%) | 7.2 (6.7, 7.7) | 7.6 (7.2, 8.1) | 6.6 (6.3, 6.8) |
| Post‐BMI (kg/m2) | 24.2 (22.0, 26.7) | 24.4 (22.1, 26.8) | 23.8 (21.8, 26.6) |
| Post‐HbA1c (%) | 7.1 (6.6, 7.6) | 7.4 (7.0, 8.0) | 6.5 (6.2, 6.8) |
| ΔBMI (kg/m2) | 0.04 (–0.27, 0.33) | 0.04 (–0.28, 0.32) | 0.06 (–0.26, 0.35) |
| ΔHbA1c (%) | –0.1 (–0.4, 0.1) | –0.2 (–0.5, 0.1) | 0 (–0.2, 0.1) |
| Days between pre‐ and post‐visit (days) | 97 (84, 112) | 96 (84, 112) | 98 (84, 119) |
| Average days between clinic visits during emergency period (days) | 70 (54.5, 98) | 66.5 (49, 97) | 84 (59.5, 98) |
| Average days between clinic visits and/or telemedicine (days) | 52.5 (41, 63) | 49 (37.3, 63) | 56 (45.5, 66.5) |
Data are the median (interquartile range) or number (%).
BMI, body mass index; HbA1c, glycated hemoglobin.
Multiple linear regression analysis of HbA1c at post‐period (post‐HbA1c)
| Independent variables in the model | β | β′ |
| Model |
|---|---|---|---|---|
| Model 1 (all participants, | ||||
| Average days between clinic visits | 0.00069 | 0.022 | 0.038 | |
| Pre‐HbA1c | 0.79610 | 0.820 | <0.001 | |
| Pre‐BMI | 0.01678 | 0.073 | <0.001 | 0.698 |
| ΔBMI | 0.13517 | 0.083 | <0.001 | |
| Age | 0.00363 | 0.046 | <0.001 | |
| Model 2 (all participants, | ||||
| Average days between clinic visits and/or telemedicine | 0.00148 | 0.031 | 0.004 | |
| Pre‐HbA1c | 0.79675 | 0.821 | <0.001 | |
| Pre‐BMI | 0.01704 | 0.074 | <0.001 | 0.698 |
| ΔBMI | 0.13458 | 0.083 | <0.001 | |
| Age | 0.00388 | 0.049 | <0.001 | |
| Model 3 (participants with pre‐HbA1c ≥7.0%, | ||||
| Average days between clinic visits and/or telemedicine | 0.00351 | 0.077 | <0.001 | |
| Pre‐HbA1c | 0.73916 | 0.712 | <0.001 | |
| Pre‐BMI | 0.02494 | 0.118 | <0.001 | 0.554 |
| ΔBMI | 0.13944 | 0.091 | <0.001 | |
| Age | 0.00541 | 0.074 | <0.001 | |
| Model 4 (participants with pre‐HbA1c ≥7.0%, | ||||
| Visiting the clinic | –0.13969 | –0.080 | <0.001 | |
| Telemedicine | –0.09261 | –0.054 | 0.004 | |
| Pre‐HbA1c | 0.74115 | 0.714 | <0.001 | 0.553 |
| Pre‐BMI | 0.02477 | 0.117 | <0.001 | |
| ΔBMI | 0.13568 | 0.088 | <0.001 | |
| Age | 0.00530 | 0.072 | <0.001 | |
All models are adjusted for sex and type of diabetes.
β and β′ denotes regression coefficient and standardized regression coefficient, respectively.
BMI, body mass index; HbA1c, glycated hemoglobin.
Multiple logistic regression analysis of whether HbA1c at post‐period (post‐HbA1c) reached <7.0%
| Independent variables in the model | Multiple‐adjusted odds ratios (95% CI) |
|
|---|---|---|
| Model 1 (participants with pre‐HbA1c ≥7.0%, | ||
| Average weeks between clinic visits and/or telemedicine | 0.92 (0.87–0.97) | 0.003 |
| Pre‐HbA1c per 0.1% increase | 0.80 (0.77–0.83) | <0.001 |
| Pre‐BMI per 1 kg/m2 increase | 0.95 (0.92–0.99) | 0.007 |
| ΔBMI per 1 kg/m2 increase | 0.45 (0.35–0.57) | <0.001 |
| Age per 5 years | 0.89 (0.83–0.94) | <0.001 |
| Model 2 (participants with pre‐HbA1c ≥7.0%, | ||
| Visiting the clinic | 1.53 (1.12–2.08) | 0.007 |
| Telemedicine | 1.56 (1.15–2.11) | 0.004 |
| Pre‐HbA1c per 0.1% increase | 0.80 (0.77–0.83) | <0.001 |
| Pre‐BMI per 1 kg/m2 increase | 0.95 (0.91–0.99) | 0.006 |
| ΔBMI per 1 kg/m2 increase | 0.45 (0.35–0.58) | <0.001 |
| Age per 5 years | 0.88 (0.83–0.94) | <0.001 |
The multiple adjusted odds ratios are adjusted for sex and type of diabetes.
BMI, body mass index; CI, confidence interval; HbA1c, glycated hemoglobin.